Gentix provides trading update

19 January 2009

New Milton, UK-based Genetix Group, a cell imaging and analysis firm, has provided an update on trading ahead of its preliminary results for  the year ended 31 December 2008, which are expected to be announced in  early March.

Revenue for the year is expected to increase by around 14% to about  GBP26.2 million ($38.9 million) driven by good growth in clinical  instruments, cell biology and the recurring revenue streams of  consumables and services. The company's genomics-based instruments  revenues are expected to be broadly similar to 2007. Revenue in the  year was positively impacted by around GBP800,000 by the strengthening US  dollar against sterling.

The Group continues to be strongly cash generative and is expected to  finish the year with cash of GBP15.2 million (2007: GBP12.6 million) and no  borrowings. Underlying pretax profits and earnings per share are  expectted to be inline with market expectations, the firm says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight